The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can
aid in objectively diagnosing patients and providing individualized treatment …

Major depressive disorder (MDD) was previously hypothesized to be a disease of
monoamine deficiency in which low levels of monoamines in the synaptic cleft were …

Ketamine is an open channel blocker of ionotropic glutamatergic N-Methyl-D-Aspartate
(NMDA) receptors. The discovery of its rapid antidepressant effects in patients with …

The pathophysiology of major depressive disorder (MDD) is thought to result from impaired
connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key …

Social isolation and discrimination are growing public health concerns associated with poor
physical and mental health. They are risk factors for increased morbidity and mortality and …

The mechanisms underlying the pathophysiology and treatment of depression and stress-
related disorders remain unclear, but studies in depressed patients and rodent models are …

Our understanding of depression and its treatment has advanced with the advent of
ketamine as a rapid-acting antidepressant and the development and refinement of tools …

The microbiota-gut-brain axis has emerged as a novel target in depression, a disorder with
low treatment efficacy. However, the field is dominated by underpowered studies focusing …

Objective: Altered glutamatergic neurotransmission has been implicated in the pathogenesis
of depression. This trial evaluated the efficacy and safety of AXS-05 (dextromethorphan …

Identification of intrinsic brain activity differences and similarities between major depression
(MDD) and bipolar disorder (BD) is necessary. However, results have not yet yielded …